

# Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Last Update: Feb 04, 2025

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)

ClinicalTrials.gov Identifier:

[NCT05755386](#)

Novartis Reference Number:CLNP023B12302

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis. The purpose of this Phase III study is to evaluate the efficacy and safety of iptacopan compared to placebo (both administered in combination with standard of care) in participants (adults and adolescents aged 12-17 years) with idiopathic IC-MPGN. The study aims to demonstrate a reduction in proteinuria and improvement in estimated glomerular filtration rate (eGFR) in participants treated with iptacopan compared to placebo. Change in patient-reported fatigue will also be evaluated. Alternative complement pathway (AP) dysregulation is believed to underlie the clinical manifestations and progression of IC-MPGN. Upon completion of study treatment, participants will have the option to discontinue iptacopan treatment and enter a 30 day safety follow-up or continue iptacopan treatment by transitioning to an open label extension study (CLNP023B12001B; NCT03955445) and continue iptacopan treatment.

Condition

IC-MPGN

Phase

Phase3

Overall Status

Recruiting

Number of Participants

106

Start Date

Oct 02, 2023

Completion Date

May 29, 2029

Gender

All

Age(s)

12 Years - 60 Years (Child, Adult)

## Interventions

Drug

### iptacopan

iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

Drug

### Placebo

Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

## Eligibility Criteria

Inclusion Criteria:

- \* Male and female patients including adults (aged at least 18 years to  $\leq 60$  years) and adolescents (12 -17 years in non-EU countries at screening and 16-17 years in EU countries at screening).
- \* Diagnosis of idiopathic IC-MPGN as confirmed by kidney biopsy within 12 months prior to screening in adults and within 3 years of screening in adolescents (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available in an adult participant, this must be obtained at screening (performed and assessed locally for adults only).
- \* Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of renin angiotensin system inhibitors (RASi), e.g an ACEi or ARB for at least 90 days (or as according to local guidelines). The doses of other drugs administered to reduce proteinuria and control the disease including mycophenolic acids (MPAs - mycophenolate mofetil or mycophenolate sodium), corticosteroids, SGLT2 inhibitors and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization
- \* UPCR  $\geq 1.0$  g/g ( $\geq 113$  mg/mmol) sampled from the first morning void urine sample at Day -75 and Day -15
- \* Estimated GFR (using the chronic kidney disease [CKD]-EPI formula for adult participants and modified Schwartz formula for adolescents aged 12 to 17 years) or measured GFR  $\geq 30$  ml/min/1.73m<sup>2</sup> at screening and Day -15.
- \* Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment. If the participant has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If the study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated in accordance with local standard of care.
- \* If not previously vaccinated, or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration.

Exclusion Criteria:

- \* Participants who have undergone cell or solid organ transplantation, including kidney transplantation.
- \* Participants diagnosed with secondary IC-MPGN including but not limited to any of the following conditions:

- \* Deposition of antigen-antibody immune complexes as a result of any chronic infections, including
- \* Hepatitis C virus (HCV) including HCV-associated mixed cryoglobulinemia, hepatitis B virus (HBV);
- \* Bacterial-endocarditis, infected ventriculo-atrial shunt, visceral abscesses, leprosy, meningococcal meningitis; chronic bacterial infections
- \* Protozoa/other infections- malaria, schistosomiasis, mycoplasma, leishmaniasis, filariasis, histoplasmosis

Renal deposition of immune complexes as a result of a systemic autoimmune disease:

- \* Systemic lupus erythematosus (SLE)
- \* Sjögren syndrome
- \* Rheumatoid arthritis
- \* Mixed connective tissue disease Deposition of monoclonal immunoglobulins because of a monoclonal gammopathy due to plasma cell or B cell disorders. Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care.

Fibrillary glomerulonephritis

- \* Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months with kidney biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli on the most recent biopsy.
- \* Kidney biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%.
- \* Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever  $\geq 38^{\circ}\text{C}$  ( $100.4^{\circ}\text{F}$ ) within 7 days prior to study treatment administration.
- \* A history of recurrent invasive infections caused by encapsulated organisms, e.g., *Neisseria meningitidis* and *Streptococcus pneumoniae*.
- \* The use of inhibitors of complement factors (e.g., Factor B, Factor D, complement 3 (C3) inhibitors, anti-Complement 5 (C5) antibodies, C5a receptor antagonists) within 3 months or 5 half-lives prior to the Screening visit.
- \* The use of immunosuppressants (except MPAs), cyclophosphamide or systemic corticosteroids at a dose  $>7.5$  mg/day (or equivalent for a similar corticosteroid medication) within 90 days of study drug administration.
- \* The use of MPAs is not permitted within 90 days prior to randomization in India, as per the local health authority requirement.
- \* Acute post-infectious glomerulonephritis at screening, based upon the opinion of the investigator.
- \* Body mass index (BMI)  $>38$  kg/m<sup>2</sup> at screening and randomization. Body weight  $<35$  kg at screening and randomization

## **Argentina**

### **Novartis Investigative Site**

Recruiting

Caba,Buenos Aires,C1425agc,Argentina

### **Novartis Investigative Site**

Recruiting

Buenos Aires,W3400abh,Argentina

## **Brazil**

### **Novartis Investigative Site**

Recruiting

Botucatu,SP,18618-970,Brazil

### **Novartis Investigative Site**

Recruiting

Brasilia,DF,71635-580,Brazil

### **Novartis Investigative Site**

Recruiting

Santo Andre,SP,09090-790,Brazil

### **Novartis Investigative Site**

Recruiting

Belo Horizonte,MG,30150-221,Brazil

### **Novartis Investigative Site**

Recruiting

Sao Paulo,SP,04038-002,Brazil

### **Novartis Investigative Site**

Recruiting

Pernambuco,Recife,50740-900,Brazil

### **Novartis Investigative Site**

Recruiting

Sao Paulo,SP,05403 000,Brazil

### **Novartis Investigative Site**

Recruiting

Niteroi,RJ,24020 096,Brazil

### **Novartis Investigative Site**

Recruiting

Sao Paulo,SP,05403-000,Brazil

**Novartis Investigative Site**

Recruiting

Rio de Janeiro,RJ,22211 230,Brazil

**Novartis Investigative Site**

Recruiting

Salvador,40301-155,Brazil

**Novartis Investigative Site**

Recruiting

Porto Alegre,RS,90035-074,Brazil

**Canada**

**Novartis Investigative Site**

Recruiting

Montreal,Quebec,H3t 1c5,Canada

**Czechia**

**Novartis Investigative Site**

Recruiting

Praha,12808,Czechia

**France**

**Novartis Investigative Site**

Recruiting

Montpellier Cedex 5,34295,France

**Novartis Investigative Site**

Recruiting

Paris,75015,France

**Novartis Investigative Site**

Recruiting

Toulouse 4,31054,France

## **Germany**

### **Novartis Investigative Site**

Recruiting

Dresden,01307,Germany

### **Novartis Investigative Site**

Recruiting

Essen,45147,Germany

### **Novartis Investigative Site**

Recruiting

Mainz,55131,Germany

### **Novartis Investigative Site**

Recruiting

Berlin,13353,Germany

## **India**

### **Novartis Investigative Site**

Recruiting

Nagpur,Maharashtra,440015,India

### **Novartis Investigative Site**

Recruiting

New Delhi,110029,India

## **Israel**

### **Novartis Investigative Site**

Recruiting

Petach Tikva,49202,Israel

### **Novartis Investigative Site**

Recruiting

Haifa,3109601,Israel

**Novartis Investigative Site**

Recruiting

Jerusalem,91031,Israel

**Italy**

**Novartis Investigative Site**

Recruiting

Torino,TO,10126,Italy

**Novartis Investigative Site**

Recruiting

Napoli,80131,Italy

**Novartis Investigative Site**

Recruiting

Bari,BA,70124,Italy

**Novartis Investigative Site**

Recruiting

Ranica,BG,24020,Italy

**Novartis Investigative Site**

Recruiting

Brescia,BS,25123,Italy

**Novartis Investigative Site**

Recruiting

Milano,MI,20122,Italy

**Novartis Investigative Site**

Recruiting

Roma,RM,00165,Italy

**Japan**

Novartis Investigative Site

**Novartis Investigative Site**

Recruiting

Osaka,558-8558,Japan

**Novartis Investigative Site**

Recruiting

Okayama-city,Okayama,700-8558,Japan

**Novartis Investigative Site**

Recruiting

Hachioji-city,Tokyo,193-0944,Japan

**Poland****Novartis Investigative Site**

Recruiting

Warszawa,02097,Poland

**Novartis Investigative Site**

Recruiting

Olsztyn,10-561,Poland

**Novartis Investigative Site**

Recruiting

Warszawa,02-006,Poland

**Spain****Novartis Investigative Site**

Recruiting

Salamanca,Castilla Y Leon,37007,Spain

**Novartis Investigative Site**

Recruiting

Barcelona,Catalunya,08036,Spain

**Novartis Investigative Site**



Recruiting

Pamplona,Navarra,31008,Spain

**Novartis Investigative Site**

Recruiting

Madrid,28040,Spain

**Novartis Investigative Site**

Recruiting

Madrid,280796,Spain

**Switzerland**

**Novartis Investigative Site**

Recruiting

Lausanne,1011,Switzerland

**Novartis Investigative Site**

Recruiting

Bern,3010,Switzerland

**Turkey**

**Novartis Investigative Site**

Recruiting

Ankara,06500,Turkey

**Novartis Investigative Site**

Recruiting

Istanbul,34093,Turkey

**Novartis Investigative Site**

Recruiting

Izmir,35575,Turkey

**Novartis Investigative Site**

Recruiting

Kocaeli,41380,Turkey

## **United Kingdom**

### **Novartis Investigative Site**

Recruiting

Cardiff,Cf14 4xw,United Kingdom

### **Novartis Investigative Site**

Recruiting

Bangor,LI57 2pw,United Kingdom

## **United States**

### **Baylor Scott and White Research**

Recruiting

Temple,Texas,76502,United States

**Mohanram Narayanan**

**Stephanie McMeen**

Phone: 254-935-5838

Email: stephanie.mcmeen@bswhealth.org

## **UCSF**

Recruiting

San Francisco,California,94115,United States

**Divya Seth**

Phone: 415-476-5892

Email: Divya.Seth@ucsf.edu

**Raymond Hsu**

### **Childrens Hospital Colorado**

Recruiting

Aurora,Colorado,80045,United States

**Bradley Dixon**

**Kati Dugan**

Phone: [720-777-1234](tel:720-777-1234)

Email: [Kati.Dugan@childrenscolorado.org](mailto:Kati.Dugan@childrenscolorado.org)

### **Massachusetts General Hospital**

Recruiting

Boston,Massachusetts,02114,United States

**Meghan Sise**

**Sherley Mejia**

Email: [smejia4@mgh.harvard.edu](mailto:smejia4@mgh.harvard.edu)

### **Col Uni Med Center New York Presby**

Recruiting

New York,New York,10032,United States

Phone: [212-304-5684](tel:212-304-5684)

**Andrew S Bomback**

### **Ronald Reagan UCLA Medical Center**

Recruiting

Los Angeles,California,90095,United States

**Lama Abdelnour**

**Rana Nikbakht Malvajerdi**

Email: [RNikbakht@mednet.ucla.edu](mailto:RNikbakht@mednet.ucla.edu)

### **University of Minnesota**

Recruiting

Minneapolis,Minnesota,55455,United States

Phone: [612-262-2750](tel:612-262-2750)

**Nattawat Klomjit**

### **Univ Cali Irvine ALS Neuromuscular**

Recruiting

Orange,California,92868,United States

**Nancy Ortega**

Email: [nghernan@hs.uci.edu](mailto:nghernan@hs.uci.edu)

Ramy Hanna

## Vietnam

### Novartis Investigative Site

Recruiting

Ho Chi Minh, 700000, Vietnam

## Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

### Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

### Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: [novartis.email@novartis.com](mailto:novartis.email@novartis.com)

---

**Source URL:** <https://prod1.novartis.com/clinicaltrials/study/nct05755386>

### List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05755386>
2. [#trial-eligibility](#)
3. <tel:254-935-5838>
4. <mailto:stephanie.mcmeen@bswhealth.org>
5. <tel:415-476-5892>
6. <mailto:Divya.Seth@ucsf.edu>
7. <tel:720-777-1234>
8. <mailto:Kati.Dugan@childrenscolorado.org>
9. <mailto:smejia4@mgh.harvard.edu>
10. <tel:212-304-5684>
11. <mailto:RNikbakht@mednet.ucla.edu>
12. <tel:612-262-2750>
13. <mailto:nghernan@hs.uci.edu>
14. <tel:+41613241111>
15. <mailto:>
16. <tel:1-888-669-6682>
17. <mailto:novartis.email@novartis.com>